Topical Diacerein in Psoriasis Vulgaris

Starting soon · Phase 4 · Has a placebo group

Conditions studied: Psoriasis Vulgaris

In brief

The goal of this clinical trial is to evaluate the safety and effectiveness of topical diacerein in adults with psoriasis vulgaris. The primary objective of the study is to compare the proportion of participants who achieve a clinically meaningful improvement in disease severity between the topical diacerein group and the placebo group. Participants will: Be assigned to receive topical diacerein 1% or placebo twice daily for a treatment period of 2 months. Attend follow-up visits at Weeks 2, 4, 6, and 8. Undergo an additional evaluation one month after treatment cessation.

Key facts

Study ID

NCT07352306

Run by

Cairo University

People needed

60

Starts

2026-02-01

Expected to finish

2027-05-01

Last updated by the study team

2026-01-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years old of both genders.
• Patients with mild chronic plaque psoriasis body surface area (BSA < 10%) along with Psoriasis Area and Severity Index (PASI) score of < 10, and/or Dermatology Life Quality Index (DLQI) score of <10.

You may not qualify if…

• Documented hypersensitivity or idiosyncratic reaction to the investigational product or any excipients contained within the cream formulation.
• Intake of anti-psoriatic systemic therapy within the last 3 months, or topical treatments within the last 2 weeks.
• Patients with pustular psoriasis.
• Pregnant and breast-feeding individuals.
• Patients with psoriatic arthritis.

Where it is running

• Kasr Al-Ainy Psoriasis Unit — Cairo, Egypt

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.